18,99 €
inkl. MwSt.

Versandfertig in über 4 Wochen
  • Broschiertes Buch

PRAISE FOR The Merck Druggernaut "Few business stories involve life and death. This one does, and Fran Hawthorne tells it with insight and verve. This is an important book for anyone who has ever taken a pill or prescribed one (or bought a pharmaceutical share). It ought to be read as carefully as the directions on a prescription bottle." -Firth Calhoun, Editor at Large, Institutional Investor "Fran Hawthorne has produced a compelling, detail-rich account of how the once-mighty Merck has fallen from its perch atop the drug industry amid the turmoil that has shaken all the players in the…mehr

Produktbeschreibung
PRAISE FOR The Merck Druggernaut "Few business stories involve life and death. This one does, and Fran Hawthorne tells it with insight and verve. This is an important book for anyone who has ever taken a pill or prescribed one (or bought a pharmaceutical share). It ought to be read as carefully as the directions on a prescription bottle." -Firth Calhoun, Editor at Large, Institutional Investor "Fran Hawthorne has produced a compelling, detail-rich account of how the once-mighty Merck has fallen from its perch atop the drug industry amid the turmoil that has shaken all the players in the business. Anyone seeking to understand the vast changes this critical industry has undergone in recent years should read The Merck Druggernaut." -Hilary Rosenberg, author of The Vulture Investors and A Traitor to His Class
Autorenporträt
FRAN HAWTHORNE, a senior contributing editor of Institutional Investor, has connections deep within the business and finance communities. Hawthorne has been covering business and healthcare for more than twenty years for such publications as Fortune, BusinessWeek, and Crain's New York Business. She is the author of Inside the FDA, which is also published by Wiley.